Theralase Technologies Net Income
| TLTFF Stock | USD 0.22 0.02 10.00% |
As of the 5th of February, Theralase Technologies has the Semi Deviation of 4.6, risk adjusted performance of 0.104, and Coefficient Of Variation of 773.9. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Theralase Technologies, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Theralase Technologies, which can be compared to its competition. Please validate Theralase Technologies variance, as well as the relationship between the maximum drawdown and semi variance to decide if Theralase Technologies is priced more or less accurately, providing market reflects its prevalent price of 0.22 per share. As Theralase Technologies appears to be a penny stock we also recommend to double-check its total risk alpha numbers.
Theralase Technologies' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Theralase Technologies' valuation are provided below:Theralase Technologies does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Theralase |
Theralase Technologies 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Theralase Technologies' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Theralase Technologies.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Theralase Technologies on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Theralase Technologies or generate 0.0% return on investment in Theralase Technologies over 90 days. Theralase Technologies is related to or competes with Novacyt SA, Cynata Therapeutics, Sernova Corp, Bioqual, PetVivo Holdings, and Medical Developments. Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo d... More
Theralase Technologies Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Theralase Technologies' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Theralase Technologies upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 9.92 | |||
| Information Ratio | 0.1203 | |||
| Maximum Drawdown | 38.57 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 15.38 |
Theralase Technologies Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Theralase Technologies' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Theralase Technologies' standard deviation. In reality, there are many statistical measures that can use Theralase Technologies historical prices to predict the future Theralase Technologies' volatility.| Risk Adjusted Performance | 0.104 | |||
| Jensen Alpha | 0.8733 | |||
| Total Risk Alpha | 0.3887 | |||
| Sortino Ratio | 0.0877 | |||
| Treynor Ratio | 0.9774 |
Theralase Technologies February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.104 | |||
| Market Risk Adjusted Performance | 0.9874 | |||
| Mean Deviation | 4.69 | |||
| Semi Deviation | 4.6 | |||
| Downside Deviation | 9.92 | |||
| Coefficient Of Variation | 773.9 | |||
| Standard Deviation | 7.23 | |||
| Variance | 52.34 | |||
| Information Ratio | 0.1203 | |||
| Jensen Alpha | 0.8733 | |||
| Total Risk Alpha | 0.3887 | |||
| Sortino Ratio | 0.0877 | |||
| Treynor Ratio | 0.9774 | |||
| Maximum Drawdown | 38.57 | |||
| Value At Risk | (9.52) | |||
| Potential Upside | 15.38 | |||
| Downside Variance | 98.43 | |||
| Semi Variance | 21.14 | |||
| Expected Short fall | (10.60) | |||
| Skewness | 0.9064 | |||
| Kurtosis | 3.09 |
Theralase Technologies Backtested Returns
Theralase Technologies appears to be out of control, given 3 months investment horizon. Theralase Technologies owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.12, which indicates the firm had a 0.12 % return per unit of risk over the last 3 months. By inspecting Theralase Technologies' technical indicators, you can evaluate if the expected return of 0.88% is justified by implied risk. Please review Theralase Technologies' Risk Adjusted Performance of 0.104, semi deviation of 4.6, and Coefficient Of Variation of 773.9 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Theralase Technologies holds a performance score of 9. The entity has a beta of 0.95, which indicates possible diversification benefits within a given portfolio. Theralase Technologies returns are very sensitive to returns on the market. As the market goes up or down, Theralase Technologies is expected to follow. Please check Theralase Technologies' jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether Theralase Technologies' existing price patterns will revert.
Auto-correlation | -0.86 |
Excellent reverse predictability
Theralase Technologies has excellent reverse predictability. Overlapping area represents the amount of predictability between Theralase Technologies time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Theralase Technologies price movement. The serial correlation of -0.86 indicates that approximately 86.0% of current Theralase Technologies price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.86 | |
| Spearman Rank Test | -0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Theralase Technologies reported net income of (4.41 Million). This is 101.29% lower than that of the Health Care Equipment & Supplies sector and 101.85% lower than that of the Health Care industry. The net income for all United States stocks is 100.77% higher than that of the company.
Theralase Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theralase Technologies' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Theralase Technologies could also be used in its relative valuation, which is a method of valuing Theralase Technologies by comparing valuation metrics of similar companies.Theralase Technologies is currently under evaluation in net income category among its peers.
Theralase Fundamentals
| Return On Equity | -1.13 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (5.50) % | |||
| Current Valuation | 51.77 M | |||
| Shares Outstanding | 216.5 M | |||
| Shares Owned By Insiders | 2.56 % | |||
| Price To Earning | (9.16) X | |||
| Price To Book | 20.01 X | |||
| Price To Sales | 52.92 X | |||
| Revenue | 780.64 K | |||
| Gross Profit | 278.88 K | |||
| EBITDA | (4.13 M) | |||
| Net Income | (4.41 M) | |||
| Cash And Equivalents | 1.46 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 494.32 K | |||
| Debt To Equity | 0.19 % | |||
| Current Ratio | 2.49 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (4.03 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 12 | |||
| Beta | 1.92 | |||
| Market Capitalization | 61.59 M | |||
| Total Asset | 5.94 M | |||
| Z Score | 74.4 | |||
| Net Asset | 5.94 M |
About Theralase Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theralase Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theralase Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theralase Technologies based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Theralase OTC Stock
Theralase Technologies financial ratios help investors to determine whether Theralase OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Theralase with respect to the benefits of owning Theralase Technologies security.